Financial giants have made a conspicuous bearish move on Eli Lilly and Co. Our analysis of options history for Eli Lilly and Co LLY revealed 80 unusual trades.
Delving into the details, we found 35% of traders were bullish, while 65% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $376,787, and 70 were calls, valued at $3,597,056.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $420.0 to $1000.0 for Eli Lilly and Co over the last 3 months.
Volume & Open Interest Trends
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly and Co's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly and Co's whale trades within a strike price range from $420.0 to $1000.0 in the last 30 days.
Eli Lilly and Co 30-Day Option Volume & Interest Snapshot
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BEARISH | 01/16/26 | $780.00 | $118.3K | 21 | 43 |
| LLY | CALL | SWEEP | BULLISH | 06/21/24 | $830.00 | $100.0K | 258 | 25 |
| LLY | CALL | SWEEP | BULLISH | 04/19/24 | $710.00 | $93.0K | 164 | 21 |
| LLY | CALL | TRADE | BULLISH | 01/17/25 | $700.00 | $81.3K | 760 | 0 |
| LLY | CALL | SWEEP | BULLISH | 03/15/24 | $820.00 | $75.8K | 668 | 224 |
About Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Having examined the options trading patterns of Eli Lilly and Co, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Where Is Eli Lilly and Co Standing Right Now?
- Currently trading with a volume of 1,355,746, the LLY's price is up by 2.07%, now at $798.28.
- RSI readings suggest the stock is currently may be overbought.
- Anticipated earnings release is in 52 days.
Professional Analyst Ratings for Eli Lilly and Co
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $816.0.
- An analyst from Wells Fargo has decided to maintain their Overweight rating on Eli Lilly and Co, which currently sits at a price target of $825.
- Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Eli Lilly and Co with a target price of $805.
- In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $815.
- In a cautious move, an analyst from DZ Bank downgraded its rating to Hold, setting a price target of $820.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $815.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly and Co with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
